相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
Atsushi Hiraoka et al.
CANCER REPORTS (2022)
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Josep M. Llovet et al.
HEPATOLOGY (2021)
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Masatoshi Kudo et al.
LIVER CANCER (2021)
Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib
Toshifumi Tada et al.
SCIENTIFIC REPORTS (2021)
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
Atsushi Hiraoka et al.
SCIENTIFIC REPORTS (2021)
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
Masatoshi Kudo et al.
LIVER CANCER (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib
Yuwa Ando et al.
ONCOLOGY (2020)
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
Masatoshi Kudo et al.
GUT (2020)
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis
Atsushi Hiraoka et al.
LIVER CANCER (2019)
Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan
Atsushi Hiraoka et al.
LIVER CANCER (2019)
Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma
Yuji Eso et al.
CANCERS (2019)
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka et al.
ONCOLOGY (2019)
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study
Masatoshi Kudo et al.
CANCERS (2019)
Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study
Tsuyoshi Shimamura et al.
TRANSPLANT INTERNATIONAL (2019)
Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma
Omar Elshaarawy et al.
WORLD JOURNAL OF HEPATOLOGY (2019)
Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization
Yutaka Yasui et al.
HEPATOLOGY RESEARCH (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization
Jin Hyoung Kim et al.
LIVER INTERNATIONAL (2017)
Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function
Atsushi Hiraoka et al.
LIVER CANCER (2017)
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis
Atsushi Hiraoka et al.
DIGESTIVE DISEASES (2017)
Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma
Atsushi Hiraoka et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Proposed New Sub-Grouping for intermediate-Stage Hepatotceliular Carcinoma Using Albumin-Bilirubin Grade
Atsushi Hiraoka et al.
ONCOLOGY (2016)
Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)
Norihiro Kokudo et al.
HEPATOLOGY RESEARCH (2015)
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma
Tadaaki Arizumi et al.
LIVER CANCER (2015)
EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease
JOURNAL OF HEPATOLOGY (2015)
The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE
Florian Hucke et al.
JOURNAL OF HEPATOLOGY (2014)
Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update
Masatoshi Kudo et al.
ONCOLOGY (2014)
Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization
Sadahisa Ogasawara et al.
ONCOLOGY (2014)
Intermediate hepatocellular carcinoma: current treatments and future perspectives
J-F Dufour et al.
ANNALS OF ONCOLOGY (2013)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Epidemiology of Hepatocellular Carcinoma Consider the Population
Sahil Mittal et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2013)
Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions
Luigi Bolondi et al.
SEMINARS IN LIVER DISEASE (2012)
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid-enhanced MR Imaging
Katsuhiro Sano et al.
RADIOLOGY (2011)
Intraindividual Comparison of Gadoxetate Disodium-enhanced MR Imaging and 64-Section Multidetector CT in the Detection of Hepatocellular Carcinoma in Patients with Cirrhosis
Michele Di Martino et al.
RADIOLOGY (2010)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment
Atsushi Hiraoka et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Management of hepatoceullular carcinoma
J Bruix et al.
HEPATOLOGY (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score
M Kudo et al.
HEPATOLOGY (2004)
Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score)
M Kudo et al.
JOURNAL OF GASTROENTEROLOGY (2003)
Estimating the world cancer burden: GLOBOCAN 2000
DM Parkin et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
分享论文
